Julia M L Brotherton1, Gina S Ogilvie. 1. aNational HPV Vaccination Program Register, East Melbourne bSchool of Population and Global Health, University of Melbourne, Victoria, Australia cSchool of Population and Public Health, University of British Columbia, Vancouver dWomen's Health Research Institute, BC Women's Health Centre, Vancouver, British Columbia, Canada.
Abstract
PURPOSE OF REVIEW: In this article, we review the impact of the quadrivalent and bivalent prophylactic human papillomavirus (HPV) vaccines on HPV infection and disease, review alternative vaccine dosing schedules, the vaccination of men and the nine-valent HPV vaccine. RECENT FINDINGS: HPV vaccines have had dramatic impacts on the prevalence of targeted HPV types (6,11,16 and 18), genital warts and precancerous cervical lesions. Population coverage would be facilitated by adopting two-dose schedules, with recent findings that two-dose schedules in young adolescents are as immunogenic as three doses in young adults. Extension of vaccination to men, particularly for men who have sex with men, could further reduce population prevalence of HPV and provide direct protection to men against genital warts and anal, penile and oropharyngeal cancers. The nine-valent HPV vaccine has demonstrated equivalent protection against the four types in the quadrivalent vaccine and high efficacy against the next five commonest causes of cervical cancer (HPV types 31,33,45,52 and 58). If cost-effective, it may extend the spectrum of protection against cervical cancer available through vaccination. SUMMARY: HPV vaccination is an effective strategy for reducing the burden of HPV-related disease. New schedules, target populations and vaccines promise to expand this potential further.
PURPOSE OF REVIEW: In this article, we review the impact of the quadrivalent and bivalent prophylactic human papillomavirus (HPV) vaccines on HPV infection and disease, review alternative vaccine dosing schedules, the vaccination of men and the nine-valent HPV vaccine. RECENT FINDINGS:HPV vaccines have had dramatic impacts on the prevalence of targeted HPV types (6,11,16 and 18), genital warts and precancerous cervical lesions. Population coverage would be facilitated by adopting two-dose schedules, with recent findings that two-dose schedules in young adolescents are as immunogenic as three doses in young adults. Extension of vaccination to men, particularly for men who have sex with men, could further reduce population prevalence of HPV and provide direct protection to men against genital warts and anal, penile and oropharyngeal cancers. The nine-valent HPV vaccine has demonstrated equivalent protection against the four types in the quadrivalent vaccine and high efficacy against the next five commonest causes of cervical cancer (HPV types 31,33,45,52 and 58). If cost-effective, it may extend the spectrum of protection against cervical cancer available through vaccination. SUMMARY:HPV vaccination is an effective strategy for reducing the burden of HPV-related disease. New schedules, target populations and vaccines promise to expand this potential further.
Authors: Leila A Haidari; Shawn T Brown; Dagna Constenla; Eli Zenkov; Marie Ferguson; Gatien de Broucker; Sachiko Ozawa; Samantha Clark; Allison Portnoy; Bruce Y Lee Journal: Sex Transm Dis Date: 2017-04 Impact factor: 2.830
Authors: Carlos R Oliveira; Robert M Rock; Eugene D Shapiro; Xiao Xu; Lisbet Lundsberg; Liye B Zhang; Aileen Gariepy; Jessica L Illuzzi; Sangini S Sheth Journal: Am J Obstet Gynecol Date: 2017-12-06 Impact factor: 10.693
Authors: Leila H Abdullahi; Benjamin M Kagina; Valantine Ngum Ndze; Gregory D Hussey; Charles S Wiysonge Journal: Cochrane Database Syst Rev Date: 2020-01-17
Authors: Phetsavanh Chanthavilay; Daniel Reinharz; Mayfong Mayxay; Keokedthong Phongsavan; Donald E Marsden; Lynne Moore; Lisa J White Journal: BMC Health Serv Res Date: 2016-08-22 Impact factor: 2.655
Authors: Andrea Garolla; Luca De Toni; Alberto Bottacin; Umberto Valente; Maurizio De Rocco Ponce; Andrea Di Nisio; Carlo Foresta Journal: Sci Rep Date: 2018-01-17 Impact factor: 4.379